Drug Trial Radar · NCT05724199
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
746
Actual
Start
Feb 21, 2023
Primary completion
Sep 15, 2024
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The coprimary objectives of the study are to: * evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). * evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI).
Conditions
- Atopic Dermatitis
Interventions
RocatinlimabDrug
Subcutaneous (SC) injection
PlaceboOther
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Time frame: Baseline and Week 24
- Number of Participants Who Achieved ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24Time frame: Baseline and Week 24
Locations
234 sites in 26 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Medical Dermatology Specialists
Phoenix, Arizona
Southwest Skin Specialists
Phoenix, Arizona
US Dermatology Partners Sun City West
Sun City West, Arizona
Arkansas Research Trials, LLC
North Little Rock, Arkansas
Kern Research Inc
Bakersfield, California
Keck Medicine of University of Southern California
Los Angeles, California
Wallace Medical Group Inc
Los Angeles, California
Antelope Valley Clinical Trials
Palmdale, California
University of California at Davis Medical Center
Sacramento, California
Kaiser Permanente South Sacramento Medical Center
Sacramento, California
Acclaim Clinical Research
San Diego, California
Kaiser Permanente Medical Center - Oakland
San Francisco, California
Kaiser Permanente Medical Center - San Francisco
San Francisco, California
Synergy Dermatology
San Francisco, California
TrueBlue Clinical Research
Tampa, Florida
Olympian Clinical Research - Tampa
Tampa, Florida
Atlanta Dermatology, Vein and Research Center, PC
Alpharetta, Georgia
Divine Dermatology and Aesthetics
Atlanta, Georgia
NorthShore University HealthSystem
Skokie, Illinois
DS Research
Clarksville, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Dermatology and Skin Cancer Center Leawood
Leawood, Kansas
Industrial Medicine Associates Clinical Research Advanced Dermatology Care
Monroe, Louisiana
Aesthetic and Dermatology Center
Rockville, Maryland
University of Michigan Medical Center
Ann Arbor, Michigan
Oakland Hills Dermatology
Auburn Hills, Michigan
Somnos Clinical Research
Lincoln, Nebraska
Skin Specialists PC
Omaha, Nebraska
Vivida Dermatology
Las Vegas, Nevada
Las Vegas Clinical Trials
North Las Vegas, Nevada
Schweiger Dermatology Group, PC Research Division
Hackensack, New Jersey
Albuquerque Clinical Trials Incorporated
Albuquerque, New Mexico
Chear Center LLC
The Bronx, New York
Accellacare of Wilmington
Wilmington, North Carolina
Bexley Dermatology Research
Bexley, Ohio
Velocity Clinical Research Inc
Medford, Oregon
Paddington Testing Company Inc
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Health Concepts
Rapid City, South Dakota
Showing 40 of 234 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.